JAZZ News and Press, Jazz Pharmaceuticals plc From 02/25/20

DUBLIN , Feb. 25, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2019 and provided financial guidance for 2020. "With more than $2 billion of revenue and double-digit top- and bottom-li...

Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) are up 30% at 2:24 p.m. EST after the biotech sold 8,680,225 American depositary shares and 487,614 shares of Series A nonvoting convertible preferred shares for $7.09 each in a private placement, grossing the company $65 million. Shares of Ava...

Prescription Drug User Fee Act (PDUFA) date set for August 16, 2020 . MADRID and DUBLIN , Feb. 17, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority R...

DUBLIN , Feb. 11, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 fourth quarter and full year financial results on Tuesday, February 25, 2020 , after the close of the financial markets.  Company management will host a l...

When it comes to buy-and-hold investing, you can't go wrong with growth or value stocks. However, research from Bank of America /Merrill Lynch tells us that one category does offer a higher return over the long haul. According to a 2016 report that analyzed data over a 90-year period, beginni...

So far, stock market tailwinds because of end of year bonuses, retirement plan contributions, and institutional re-positioning have offset data suggesting the market is overbought. However, a 3% to 5% correction is getting more likely as the rally broadens out (excluding energy), suggesting in...

Johnson & Johnson ( JNJ ) received a breather as a Philadelphia judge slashed the amount of punitive damages imposed on the company. The damages pertained to the product liability lawsuit related to antipsychotic med Risperdal or risperidone. The plaintiff was initially awarded $680K in ...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has submitted an application for Food and Drug Administration (FDA) approval of JZP-258, a new drug for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy age 7 and up. To speed along an FDA review of JZP-258, the company is r...

DUBLIN , Jan. 22, 2020 /PRNewswire/ --   Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking marketing approval for JZP-258, an investigational medicine for ...

-  PharmaMar and Jazz signed an exclusive license agreement on 19 December 2019 for lurbinectedin in the United States -  Jazz to pay an upfront payment of $200 million to PharmaMar -  PharmaMar is also eligible to receive up to $800  million ...